Background：Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A IL17A and interleukin 17F IL17F. This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified.
Alternative Names：MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110,
